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Background. Sialoadhesin (CD169, siglec-1 or Sn) is an activation marker seen on macrophages in chronic inflammatory
diseases and in tumours, and on subsets of tissue macrophages. CD169 is highly expressed by macrophages present in AIDS-
related Kaposi’s sarcoma lesions. It is also increased on blood monocytes of HIV-1 infected patients with a high viral load
despite antiretroviral treatment. Methodology/Principal Findings. We investigated expression of sialoadhesin in untreated
HIV-1 and HHV-8 infected patients, by real-time PCR and FACS analysis to establish its expression in relation to infection and
disease progression. Patients analysed were either HIV-1 seroconverters (n=7), in the chronic phase of HIV-1 infection (n=21),
or in the AIDS stage (n=58). Controls were HHV-8 infected, but otherwise healthy individuals (n=20), and uninfected men
having sex with men (n=24). Sialoadhesin mRNA was significantly elevated after HIV-1, but not HHV-8 infection, and a further
increase was seen in AIDS patients. Samples obtained around HIV-1 seroconversion indicated that sialoadhesin levels go up
early in infection. FACS analysis of PBMCs showed that sialoadhesin protein was expressed at high levels by approximately
90% of CD14
+ and CD14
+CD16
+cells of HIV-1
+ patients with a concomitant 10-fold increase in sialoadhesin protein/cell
compared with uninfected controls. Conclusions/Significance. We have shown that sialoadhesin is induced to high levels on
CD14
+ cells early after HIV-1 infection in vivo. The phenotype of the cells is maintained during disease progression, suggesting
that it could serve as a marker for infection and probably contributes to the severe dysregulation of the immune system seen
in AIDS.
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INTRODUCTION
HIV-1 infection of humans is traditionally divided into three
stages: the acute phase lasting several weeks, when viral RNA
levels are high and specific antibodies are low, followed by
a relatively long period of chronic infection starting at the moment
of seroconversion (when HIV-specific antibody tests become
positive). Finally, the combined effects of the acute and chronic
disease stage results in a total collapse of the immune system
resulting in multiple opportunistic infections: the AIDS phase.
HIV-1 infection is characterized by the expression of large
amounts of proinflammatory cytokines, which are involved in
immune suppression by promoting both CD4
+ and CD8
+ T cell
apoptosis (for a review: see [1]). The cytokine signalling systems
are further deregulated by virally encoded proteins such as Nef,
Tat and Vpr. These chronic inflammatory conditions are linked to
elevated virus production and immune dysfunction.
Applying Serial Analysis of Gene Expression (SAGE) to AIDS-
related Kaposi’s sarcoma (AIDS-KS) tissue and comparing its
expression profile to that of normal skin, revealed several
transcripts that were upregulated in AIDS-KS [2]. Of particular
interest was the sialic acid binding receptor sialoadhesin (CD169,
siglec-1 or Sn), which is seen on activated macrophages in chronic
inflammation and in tumours, e.g. on macrophages found in
multiple sclerosis, atherosclerosis, and rheumatoid arthritis [3], on
monocytes from HIV-1 infected patients treated with antiretro-
viral therapy, especially those with a high viral load [4], and on
dendritic cells infected with human rhinovirus strain 14 [5].
Sialoadhesin mediates cell-cell interactions by recognizing Neu5A-
ca2,3Gal in either N- or O-glycans on the surface of several
leukocyte subsets [3,6]. To evaluate expression of sialoadhesin
during different stages of HIV-1 infection, we investigated
sialoadhesin mRNA levels by real-time PCR in peripheral blood
mononuclear cells (PBMCs) collected from patients participating
in the Amsterdam Cohort Studies on HIV/AIDS. The expression
level of sialoadhesin in AIDS-KS was compared with four control
groups consisting of a-symptomatic HIV-1 infected patients,
HHV-8 infected patients, patients with AIDS other than AIDS-
KS, and non-infected controls belonging to the risk group (men
having sex with men). Sialoadhesin mRNA levels were also
compared in PBMCs from an additional set of patients sampled
before and after the moment of seroconversion for HIV-1
(seroconverters). FACS analysis was used to investigate whether
the upregulation of sialoadhesin represents an increased expression
per cell, or an increase in cells expressing sialoadhesin. In asymp-
tomatic HIV-1 infected patients, sialoadhesin protein expression
was increased in the total PBMC fraction, including high levels on
approximately 90% of both CD14
+ and CD14
+CD16
+cells, with
a mean two-fold expansion of the latter cell type.
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Expression of sialoadhesin mRNA
Sialoadhesin mRNA was quantified in PBMCs of patients infected
with HIV-1 and/or HHV-8 (Fig. 1A). A highly significant differ-
ence (p#0.0005) in sialoadhesin mRNA levels was seen in AIDS
patients (both AIDS-KS and non-AIDS-KS, median copy num-
bers per group ranged from 4.83610
3–2.35610
4/10
4 PBMC),
and in HIV-1 infected a-symptomatic patients (median=2.496
10
3 copies/10
4 PBMC) when compared with non-infected risk-
group patients (median=2.69610
2 copies/10
4 PBMC) or with
patients with exclusively an HHV-8 infection (median=4.286
10
2 copies/10
4 PBMC). Sialoadhesin levels between AIDS-KS
and other AIDS patients did not differ significantly (Fig. 1A).
These findings suggest that sialoadhesin mRNA is not specifically
increased in AIDS-KS, as suggested by the earlier SAGE analysis,
but is upregulated by HIV-1 infection. Differences in sialoadhesin
copy number between HIV-1
+ asymptomatics and AIDS patients,
including AIDS-KS patients, were statistically significant, with
higher expression in the AIDS group. This further upregulation
during HIV pathogenesis could be related to a difference in HIV-1
copy numbers in PMBCs, as these were, not unexpected, found
to differ significantly between AIDS and non-AIDS patients
(p#0.0001), with higher numbers in AIDS patients (Fig. 1B).
However, sialoadhesin mRNA copy numbers were only moder-
ately correlated with HIV-1 RNA copy numbers (Pearson
correlation coefficient=0.42, p=0.0002). Overall, there was
a trend that in PBMCs high HIV-1 intracellular copy numbers
accompanied high sialoadhesin mRNA copy numbers, but this
was not so for all patients. Sialoadhesin mRNA copy numbers did
not correlate with CD4
+ cell counts in AIDS patients (Pearson
correlation coefficient=20.125, p=0.51).
To analyse the effect of HIV-1 infection in more detail, sia-
loadhesin copy numbers were determined in samples from seven
HIV-1 infected patients taken before and after HIV-1 serocon-
version (Fig. 1C). The post-seroconversion sample was the first
HIV-1 positive sample identified in individuals tested at three
monthly intervals, therefore within three months of seroconver-
sion. Indeed, sialoadhesin copy numbers increased from a median
of 3.09610
2 copies/10
4 PBMC to 3.00610
3 copies/10
4 PBMC
(p=0.0016) after HIV-1 seroconversion, suggesting either an
increase of sialoadhesin mRNA in a certain cell population, the
expansion of a cell population expressing sialoadhesin after HIV-1
infection, or a loss of cells with low sialoadhesin expression, or
a combination of these.
Fluorescence-activated cell sorter (FACS) analysis of
PBMCs
Increase of sialoadhesin expression at the mRNA level as
measured by real-time PCR in our cohort could either mean that
expression per cell has increased, that the number of sialoadhesin
expressing cells has increased, or a combination of both. To
differentiate between these possibilities, we analysed CD14
+ cells
and the subset of CD14
+CD16
+ cells from three healthy donors
and three treatment-naı ¨ve, asymptomatic HIV-1 infected patients
for sialoadhesin protein expression by flow cytometry (Table 1). A
representative example of the FACS analysis is shown in Fig. 2
(panel A: CD14
+ cells, panel B: CD14
+CD16
+ cells). Staining with
mAbs for either CD14
+, CD16
+ or CD169
+ showed that siaload-
hesin expression increases dramatically in CD14
+ cell fractions,
both in positive cell numbers as well as in the amount of molecules
per cell, in HIV-1 infected patients compared with uninfected
controls (Table 1). A median of approximately 90% of CD14
+ and
CD14
+CD16
+ cells expressed sialoadhesin at levels that were
approximately 10-fold higher than in healthy donors. The number
of CD14
+CD16
+ cells is increased approximately twofold in the
PBMC population of HIV-1 infected patients compared with
healthy controls (Table 1, median increase from 2,1% to 4,6%).
The total percentage of CD14
+ cells does not change notably after
HIV-1 infection (Table 1, median percentage in healthy donors=
13,6% versus 10,4% in HIV-1 infected patients), nor does the
amount of cells not expressing CD14, CD16 and sialoadhesin
(66.47 and 67.28%, respectively), or the percentage of cells expres-
sing sialoadhesin, but not CD14 and CD16 (0.21 and 0.42%,
respectively).
DISCUSSION
Sialoadhesin mRNA and protein expression in PBMCs was
significantly increased after HIV-1 infection in vivo. An additional
raise was seen in AIDS-patients compared to asymptomatic HIV-1
infected patients. An analysis of blood samples taken before and
after HIV-1 seroconversion indicated that the initial upregulation
of sialoadhesin occurs rapidly after HIV-1 infection, and is
maintained during the chronic phase of the infection. Sialoadhesin
expression is increased after the moment of seroconversion (when
specific antibody tests become positive), which is approximately 3
months after the acute HIV infection. Possibly, sialoadhesin levels
already go up during the acute phase of the infection. However,
due to the rarity of acute phase samples, it was not feasible in this
study to assess if sialoadhesin expression is already increased in this
stage of the HIV-1 infection.
In mice, approximately 10
6 molecules/cell of sialoadhesin are
found, making it one of the most highly expressed surface molec-
ules on macrophages [7]. Levels of mRNA and protein correlate
well in mice [8]. Similar results were obtained in humans in this
study, suggesting that sialoadhesin expression is mainly regulated
at the transcriptional level, although it could be that cells with low
sialoadhesin expression disappear, or that a novel cell subset
expressing sialoadhesin emerges. Subsets of PBMC are generally
different in HIV-infected patients compared with non-infected
individuals, especially in the AIDS phase, when lymphocytes are
significantly decreased and the monocyte fraction is increased.
FACS analysis of blood cells obtained from HIV-1 infected
individuals with a relatively high viral load showed that
sialoadhesin is mainly expressed by and increased on CD14
+
cells, including CD14
+CD16
+ monocytes. The potential influence
of differences in the cellular subsets of healthy vs. HIV infected
individuals seems limited here as the total amount of CD14
+
monocytes does not differ appreciably between the two patient
groups, although the percentage of CD14
+CD16
+ monocytes is
larger after HIV-1 infection. However, to draw more firm
conclusions more patients should be analysed.
Sialoadhesin mRNA was found in a monocytic cell line,
a promonocytic cell line, cells of the myeloerythroid lineage, but
not in B-cells [3]. Expression of the protein was detected in tissue
macrophages, but not in blood monocytes from healthy donors
[3]. However, sialoadhesin was present on monocytes from
treated, chronically HIV-1 infected patients with high viral loads
[4], leading to the suggestion that these patients harbour a
circulating CD14
+ monocyte/macrophage hybrid phenotype with
chronic inflammatory characteristics.
Two monocyte subsets are currently recognized in peripheral
blood, characterized by their level of CD14 and CD16 expression
(CD14
highCD16
2, and CD14
lowCD16
+, representing approxi-
mately 90% and 10% of blood monocytes, respectively [9]). An
expansion of CD14
+CD16
+ monocytes has been observed after
HIV-1 infection [10–12] and other inflammatory conditions, while
numbers of CD14
++ monocytes do either not change [11,13], or
HIV-1 Upregulates CD169
PLoS ONE | www.plosone.org 2 February 2007 | Issue 2 | e257Figure 1. Real-time PCR analysis of sialoadhesin mRNA levels in PBMCs of HIV-1 infected patients and controls. A. Real-time PCR analysis of
sialoadhesin mRNA levels in PBMCs derived from five sets of patients with or without HIV-1 infection at different stages of disease. Patients with AIDS
but not AIDS-KS, and patients with AIDS-KS were analysed separately. Levels were significantly different (p#0.0005) between uninfected controls/
HHV-8 infected patients, and HIV-1 infected patients, respectively. Levels were also significantly different (p#0.0005) between HIV-1 infected patients
and AIDS patients. Significant differences are indicated with an asterisk. No significant differences were found between patient groups not infected
with HIV-1 (p=0.1), or between AIDS and AIDS-KS patients (p=0.14). B. Real-time PCR analysis of HIV-1 mRNA levels in PBMCs derived from either
HIV-1 infected asymptomatic patients or patients with AIDS (including AIDS-KS). The elevated HIV-1 load in AIDS patients compared to asymptomatic
HIV-1
+ patients is highly significant (p#0.0001). C. Real-time PCR analysis of sialoadhesin mRNA levels in PBMCs obtained from eight patients before
and after HIV-1 seroconversion. Sialoadhesin mRNA was analysed in the first HIV-1 seropositive sample of each patient, which is within three months
from the real seroconversion event in the Amsterdam Cohort Studies on HIV/AIDS, as samples are taken on a three-monthly basis.
doi:10.1371/journal.pone.0000257.g001
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been assumed that CD14
+CD16
+ monocytes are a distinct
‘‘proinflammatory’’ subset of the monocyte lineage [14]. However,
as CD14
+CD16
+ monocytes exhibit features of mature tissue
macrophages (such as downregulation of CD11b, CD14, and
CD33 expression, and upregulation of CD16 expression), it is also
possible that they represent either an activated or a prediffer-
entiated form of monocyte. In vitro experiments suggested the
former, as inflammatory cytokines were able to induce a CD14
+/
CD16
+- phenotype in cultured monocytes [15]. An increasing
proportion of monocytes in HIV-1 infected patients show an
activated, mature phenotype during disease progression when
tested for markers such as CD11b, HLA-DR, CD45, CD16, TNF-
alpha, PGE2, and IL-6 [13]. Furthermore, expression of several
other molecules is increased on monocytes after HIV-1 infection,
e.g. CD23 [16], CD36 [17], CD14 [11], CD126 [18], HLA-G
[19], and sialoadhesin ([4] and this study). The CD169
+
phenotype arises shortly after HIV-1 seroconversion, is maintained
during progression to AIDS, and does not specifically occur during
therapy failure, as suggested earlier [4].
Human sialoadhesin is highly upregulated in certain (inflam-
matory) diseases such as multiple sclerosis, atherosclerosis, and
rheumatoid arthritis, in breast cancer tumour-infiltrating macro-
phages [20,21], and by HIV-1 infection ([4], and this study). The
function of sialoadhesin is still not completely clear [20].
Sialoadhesin mediates cell-cell interactions by recognizing Neu5A-
ca2,3Gal in either N- or O-glycans on the surface of several
leukocyte subsets [3,6], suggesting that sialoadhesin could be
involved in adhesion processes. Monocytes (and also lymphocytes)
show increased adhesion to endothelial cells after HIV infection,
leading to an increase in cardiovascular disease, atherosclerosis
and Kaposi’s sarcoma in HIV-positive patients (reviewed in [22]).
Increased expression of sialoadhesin could be related to this
phenomenon. On the other hand, dendritic cells express
sialoadhesin after infection with human rhinovirus 14, and here
it was shown to function as an inhibitory receptor involved in
inducing anergy in T-cells [5]. CD33-related members of the
siglec family (subgroup 2) have been shown to have inhibitory
functions in the immune system [23]. It is likely that the distinct
subgroup 1 siglecs (siglec-1, -2, and –4) have similar, negative
regulatory functions in the immune system. Elevated, enduring
expression of sialoadhesin in chronic inflammatory conditions
(including HIV infection) and certain types of cancer, probably
induced by high-level cytokine expression, then has a lasting
negative, inhibitory effect on the immune system that finally results
in opportunistic infections and/or the occurrence of tumours due
to immune system malfunction. Chronic inflammation is a risk
factor for many types of cancer (for a review, see [24]), and is
characterized by immune system unresponsiveness (see e.g. [25]).
Only higher animals and a few microorganisms can synthesize
sialic acids, but some pathogens have found ways to capture these
sugars from their hosts (reviewed in [26]), possibly to provide an
immunologic disguise. In pigs, siglec-1 can act as an endocytic
receptor for Porcine Reproductive and Respiratory Syndrome Virus
(PRRSV), a single-stranded RNA virus [27], whereby sialic acids on
the virus particle are essential for infection of porcine macrophages
[28]. The HIV-1 envelope protein gp120 is highly glycosylated and
sialylated [29,30], suggesting that the presence of sialic acids on the
virion surface influences host production of sialoadhesin.
Concluding, we have shown that early after HIV-1 infection,
sialoadhesin is induced to high levels on CD14
+ cells of the blood.
The phenotype of the cells is maintained during disease pro-
gression, suggesting that it could serve as a marker for infection
and probably contributes to the severe dysregulation of the
immune system seen in AIDS.
MATERIALS AND METHODS
Patient characteristics
Blood samples were collected from participants of the Amsterdam
Cohort Studies on HIV/AIDS (www.amsterdamcohortstudies.
org). PBMCs isolated from a total of 131 individuals, all Caucasian
homosexual males, were selected for this study. They were divided
into the following groups: 24 AIDS-KS patients, 34 AIDS patients,
20 HHV-8 infected patients, 21 HIV-1 infected a-symptomatic
patients, 7 HIV-1 seroconverters, and 24 non-infected controls
belonging to the risk group (men having sex with men). Of the
AIDS-KS patients, 13 (=54%) had quantifiable HHV-8 DNA in
their PBMCs [31]. Of the non-KS AIDS patients, 5 (=15%) had
quantifiable HHV-8 DNA in their PBMCs, and 15 (44%) were
seropositive for HHV-8 in either an ORF65 and/or an ORF73
ELISA [32]. AIDS-KS patients have been analysed separately
from other AIDS patients, as high expression of sialoadhesin in
AIDS-KS lesions [2] suggested that levels of sialoadhesin could be
different in this patient group.
RNA and DNA extraction
Nucleic acids were isolated from 2.5610
5 PBMCs using silica and
guanidium thiocyanate [33] in a final elution volume of 62.5 ml.
RNA and DNA can be isolated simultaneously by this method.
Real-time quantitative PCR assay
Copy numbers of sialoadhesin were determined with TaqMan
assays using primers (upstream primer: 59CACCTCCAAGT-
Table 1. Percentage of cells expressing CD14, CD16, and/or sialoadhesin of the total PBMC fraction, as determined by FACS analysis
..................................................................................................................................................
CD14 CD16 Sialoadhesin Healthy donors: median % of total (range) HIV-1
+ patients: median % of total (range)
No No No 66.47(54.79–70.88) 67.28 (63.50–72.85)
No No Yes 0.21 (0.05–0.22) 0.42 (0.19–1.72)
Yes No No 12.67 (12.47–13.43) 0.79 (0.31–8.16)
Yes No Yes 0.88 (0.17–2.38) 9.65 (4.15–14.69)
Yes Yes No 1.99 (1.92–3.16) 0.56 (0.08–2.57)
Yes Yes Yes 0.11 (0.04–0.35) 4.00 (0.90–5.31)
No Yes No 14.67 (10.81–29.18) 10.78 (10.30–20.50)
No Yes Yes 0.01 (0.01–0.06) 0.17 (0.03–1.09)
doi:10.1371/journal.pone.0000257.t001
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PLoS ONE | www.plosone.org 4 February 2007 | Issue 2 | e257Figure 2. Expression of CD14, CD16, and sialoadhesin on monocytes from an HIV-1 infected and uninfected patient. A. Sialoadhesin (CD169)
expression on CD14
+ cells from a healthy human control (left) and an HIV-1 infected patient (right). The mean fluorescent intensity of CD169 from the
CD14
+ cells increases from 26 in the control cells (left) to 286 in the cells from the HIV-1 infected patient (right). B. CD14
+CD16
+ cells were gated and
their expression of sialoadhesin is shown in the histograms. The mean fluorescent intensity of CD169 from the CD14
+CD16
+ cells increases from 17 in
the control cells (left) to 158 in the cells from the HIV-1 infected patient (right). The data are representative of three experiments.
doi:10.1371/journal.pone.0000257.g002
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ATGTTCCTCCC 39, probe: 59AAGGGTGTGAAGATCCTC-
CTCAGCCC 39) designed with Primer Express software (ABI,
Foster City, CA, USA). First, 2.5 ml isolated RNA was converted
into cDNA following the instructions in the ABI Taqman Reverse
Transcription reagents kit (ABI, Foster City, CA, USA). Each RT
reaction contained 1 ml1 0 6RT buffer, 2.2 ml MgCl2 (25 mM),
2 ml dNTPs (10 mM) 1.5 ml random hexamers (50 mM), 0.2 RN-
ase inhibitor (20 U/ml), 0.35 ml multiscribe RT (50 U/ml), 0.35 ml
H2O and 2.5 ml sample eluate (=10,000 cell equivalents). The
RT-reaction started with 10 min. 25uC, 30 min. 48uC and 5 min.
95uC. Subsequent PCR reactions were done according to
PlatinumH Quantitative PCR Supermix UDG (Invitrogen Life
Technologies, Carlsbad, USA). Each reaction contained 10 ml
RT-reaction and 40 ml of PCR mixture consisting of 25 ml
supermix, 3.6 mM MgCl2, 0.9 mM forward primer and reverse
primer, 0.2 mM Taqman probe and 1 ml ROX reference dye (506
concentration). HIV-1 copy numbers in PBMCs were measured
with a gag-specific Taqman assay (upstream primer: 59 AAAGA-
GACCATCAATGAGGAAGCT 39, downstream primer: 59
TCTGGCCTGGTGCAATAGG 39, probe: 59 TGCACTG-
GATGCACTCTATCC CATTCTG 39). HHV-8 DNA copy
numbers in PBMCs were measured with an ORF65 Taqman
assay described earlier [31]. As a control, a DNA assay was
performed for b-actin using 5 ml eluate (=20,000 cell equivalents)
as input. The b-actin reaction conditions were the same except for
the primer and probe concentrations (0.3 mM forward and reverse
primers and 0.2 mM Taqman probe). Following the activation of
UDG (2 min, 50uC) and activation of PlatinumH Taq DNA
polymerase (10 min 95uC), 45 cycles (15 sec 95uC, and 1 min
60uC) were performed on an ABI 7700 Sequence Detection
System (ABI, Foster City, CA, USA). The threshold cycle (Ct) for
each sample of the standard curve was plotted against the input
copy number. The value of Ct was determined by the first cycle
number at which fluorescence was greater than the set threshold
value. For accurate comparison of the samples the threshold was
the same for all the experiments. Linear regression was used to
determine the copy number of the experimental samples. The
sialoadhesin copy numbers measured were converted to copies/
10
4 PBMC. All samples were tested in duplicate. As a control for
cross contamination samples consisting of distilled water were also
subjected to the isolation method and the extracts were tested with
all assays. The Ct for all these ‘‘no-template’’ samples was always
.45 cycles.
Fluorescence-activated cell sorter (FACS) analysis
PBMCs were isolated by density centrifugation on Lymphoprep
(Axis-Shield PoC AS, Norway) from three healthy donors and
three treatment-naı ¨ve asymptomatic HIV-1 infected patients with
HIV-1 plasma loads between 90,000 and 100,000 copies vRNA/
ml.
Subsequently, 0.5–1610
6 cells were used for staining. All
samples for FACS analysis were prepared within 2 hrs after blood
was drawn. Whole PBMC fraction was gated and analysed for the
expression of CD14, CD16 and CD169. Mouse anti-human
monoclonal antibodies (MAbs) against the following molecules
were used: PE-conjugated CD14 (Becton Dickinson, USA), FITC-
conjugated CD16 (Pelicluster
TM monoclonal antibodies, Sanquin,
The Netherlands), and CD169 (Serotec, UK), which was detected
with an APC-conjugated goat (F(ab’)2 anti-mouse IgG (Caltag
Laboratories). The staining order was: mouse anti-CD169, then
goat anti-mouse, and finally the directly labelled antibodies, with
washing steps in between to minimize cross-reactivity. The
samples were subsequently analysed on a FACS Caliber flow
cytometer (Becton Dickinson, USA). Unstained cells and appro-
priate isotype-matched controls were used to determine positive
CD14, CD16 and CD169 staining.
Statistical analysis
Overall comparison was done using analysis of variance
(ANOVA). If statistical significance was obtained for a variable,
a post-hoc analysis was done with application of the Student’s t test
for group-by-group comparisons. All statistical analyses were
performed with SAS software (SAS version 8.02, SAS Institute,
Cary, NC, USA).
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